H4 Orphan Pharma is pleased to inform you of the validation of a new patent for its active ingredient 554-002 in dry eye and allergic eye in Japan. This patent adds to the long list of patents obtained in this indication in the major markets.
Dry eye syndrome affects nearly 300 million people worldwide, and is a fast-growing market. As a reminder, no effective treatment currently exists in this indication.
This is the 37th patent obtained by H4 Orphan Pharma.